Alessandra Tedeschi

机构：Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ORCID：0000-0001-8724-2771

发表论文 500 篇 · 总被引 13733 次 · h-index 56

代表论文

• Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL (2025 · Blood · 被引 40)
• Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results (2025 · Journal of Clinical Oncology · 被引 25)
• Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. (2025 · Journal of Clinical Oncology · 被引 17)
• Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib (2025 · Leukemia · 被引 5)
• Overall survival outcomes with first‐line continuous ibrutinib and fixed‐duration ibrutinib‐venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age‐matched European population (2025 · HemaSphere · 被引 5)
• Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome (2025 · American Journal of Hematology · 被引 5)